PT - JOURNAL ARTICLE AU - Walker, Romy AU - Joo, Jihoon E. AU - Mahmood, Khalid AU - Clendenning, Mark AU - Como, Julia AU - Preston, Susan G. AU - Joseland, Sharelle AU - Pope, Bernard J. AU - Medeiros, Ana B. D. AU - Murillo, Brenely V. AU - Pachter, Nicholas AU - Sweet, Kevin AU - Spigelman, Allan D. AU - Groves, Alexandra AU - Gleeson, Margaret AU - Bernatowicz, Krzysztof AU - Poplawski, Nicola AU - Andrews, Lesley AU - Healey, Emma AU - Gallinger, Steven AU - Grant, Robert C. AU - Win, Aung K. AU - Hopper, John L. AU - Jenkins, Mark A. AU - Torrezan, Giovana T. AU - Rosty, Christophe AU - Macrae, Finlay A. AU - Winship, Ingrid M. AU - Buchanan, Daniel D. AU - Georgeson, Peter TI - Adenomas from individuals with pathogenic biallelic variants in the <em>MUTYH</em> and <em>NTHL1</em> genes demonstrate base excision repair tumour mutational signature profiles similar to colorectal cancers, expanding potential diagnostic and variant classification applications AID - 10.1101/2024.08.08.24311713 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.08.24311713 4099 - http://medrxiv.org/content/early/2024/08/09/2024.08.08.24311713.short 4100 - http://medrxiv.org/content/early/2024/08/09/2024.08.08.24311713.full AB - Background Colorectal cancers (CRCs) from people with biallelic germline likely pathogenic/pathogenic variants in MUTYH or NTHL1 exhibit specific single base substitution (SBS) mutational signatures, namely combined SBS18 and SBS36 (SBS18+SBS36), and SBS30, respectively. The aim was to determine if adenomas from biallelic cases demonstrated these mutational signatures at diagnostic levels.Methods Whole-exome sequencing of FFPE tissue and matched blood-derived DNA was performed on 9 adenomas and 15 CRCs from 13 biallelic MUTYH cases, on 7 adenomas and 2 CRCs from 5 biallelic NTHL1 cases and on 27 adenomas and 26 CRCs from 46 non-hereditary (sporadic) participants. All samples were assessed for COSMIC v3.2 SBS mutational signatures.Results In biallelic MUTYH cases, SBS18+SBS36 signature proportions in adenomas (mean±standard deviation, 65.6%±29.6%) were not significantly different to those observed in CRCs (76.2%±20.5%, p-value=0.37), but were significantly higher compared with non-hereditary adenomas (7.6%±7.0%, p-value=3.4x10-4). Similarly, in biallelic NTHL1 cases, SBS30 signature proportions in adenomas (74.5%±9.4%) were similar to those in CRCs (78.8%±2.4%) but significantly higher compared with non-hereditary adenomas (2.8%±3.6%, p-value=5.1x10-7). Additionally, a compound heterozygote with the c.1187G&gt;A p.(Gly396Asp) pathogenic variant and the c.533G&gt;C p.(Gly178Ala) variant of unknown significance (VUS) in MUTYH demonstrated high levels of SBS18+SBS36 in four adenomas and one CRC, providing evidence for reclassification of the VUS to pathogenic.Conclusions SBS18+SBS36 and SBS30 were enriched in adenomas at comparable proportions observed in CRCs from biallelic MUTYH and biallelic NTHL1 cases, respectively. Therefore, testing adenomas may improve the identification of biallelic cases and facilitate variant classification, ultimately enabling opportunities for CRC prevention.Competing Interest StatementRobert C. Grant received a scholarship from Pfizer and provided consulting or advisory roles for Astrazeneca, Tempus, Eisai, Incyte, Knight Therapeutics, Guardant Health, and Ipsen. All other authors have no relevant financial or non-financial interests to disclose.Funding StatementFunding by a National Health and Medical Research Council of Australia (NHMRC) Investigator grant GNT1194896 awarded to DDB and funding by a Cure Cancer Early Career Research Grant awarded to PG supported the design, analysis, and interpretation of data. DDB is supported by a University of Melbourne Dame Kate Campbell Fellowship. PG is supported by an NHMRC Investigator Grant (2026331). RW is supported by the University of Melbourne Early Career Researcher Grant. BJP is supported by a Victorian Health and Medical Research Fellowship from the Victorian Government. AKW is supported by an NHMRC Investigator grant (GNT1194392). JLH is supported by the University of Melbourne Dame Kate Campbell Fellowship. MAJ is supported by an NHMRC Investigator grant (GNT1195099). The Colon Cancer Family Registry (CCFR, www.coloncfr.org) is supported in part by funding from the National Cancer Institute (NCI), National Institutes of Health (NIH) (award U01 CA167551). Support for case ascertainment was provided in part from the Surveillance, Epidemiology, and End Results (SEER) Program and the following U.S. state cancer registries: AZ, CO, MN, NC, NH; and by the Victoria Cancer Registry (Australia) and Ontario Cancer Registry (Canada). The content of this manuscript does not necessarily reflect the views or policies of the NIH or any of the collaborating centres in the CCFR, nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government, any cancer registry, or the CCFR.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of The University of Melbourne gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.